More specifically, patients with NPM1-m (n = 9) achieved a 44% ORR and a 33% CR rate, while patients with KMT2Ar R/R AML who received at least 140 mg of the study drug (n = 12) experienced an ORR of 67% and a 42% composite CR rate. The gene discussed is NPM1; the disease is acute myeloid leukemia.